Johnson & Johnson gets $2.8B offer for its advanced sterilization business

Handshake business deal executives
Fortive is bidding $2.8 billion for Johnson & Johnson’s advanced sterilization business. (Pixabay)

Industrial equipment maker Fortive is offering to snap up Johnson & Johnson’s advanced sterilization business for about $2.8 billion, the company said.

The bid, which includes $2.7 billion in cash and $100 million in retained net receivables, is for Advanced Sterilization Products, which is a division of J&J’s Ethicon. Last year, ASP reported net revenues of about $775 million. The unit makes products used in low-temperature terminal sterilization and high-level disinfection of reusable surgical instruments.

J&J has 120 days to consider the offer and, if accepted, the deal would likely close by early next year, the company said.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Everett, Washington-based Fortive, which was spun off from from Danaher in 2016, said it plans to finance the deal through debt or equity and with available cash.

“With ASP, we expect to acquire a global leader in medical sterilization and disinfection, with a large installed base and very strong brands,” James Lico, Fortive’s president and CEO, said in a statement.

Earlier this year, private equity group Platinum Equity offered J&J $2.1 billion for LifeScan, its blood glucose monitoring business. Last year, J&J indicated it was looking to offload LifeScan along with its other diabetes device units Animas and Calibra Medical.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Hand-held ultrasound developer Butterfly Network is going public through a $1.5 billion acquisition deal backed by Glenview Capital.